Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine-Reference-Cited by-同舟云学术

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Published:2024-04-18 Issue:6 Volume:65 Page:923-930
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Hebert Kévin,Santoro Lore,Monnier Maeva,Castan Florence,Berkane Ikrame,Assénat Eric,Fersing Cyril,Gélibert Pauline,Pouget Jean-Pierre,Bardiès Manuel,Kotzki Pierre-Olivier,Deshayes Emmanuel

Publisher

Society of Nuclear Medicine

Reference29 articles.

1. WHO Classification of Tumours Editorial Board. Neuroendocrine neoplasms. In: Urinary and Male Genital Tumours . International Agency for Research on Cancer; 2022:385–397. WHO Classification of Tumours; vol. 8. 5th ed.

2. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide: a case history;Krenning;Ann N Y Acad Sci.,1994

3. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

5. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-05